Ever After Foods Ltd., a subsidiary of Nasdaq-listed Pluri Ltd. (PLUR), has acquired Fishway BV, a Belgium-based cultivated seafood platform, and closed a concurrent $2 million SAFE investment. The deal was signed on August 12, 2026, and announced publicly on August 17.
Fishway specializes in cell-cultivation technology for seafood, giving Ever After Foods an immediate European R&D and regulatory footprint. The acquisition is part of Pluri’s broader strategy to commercialize its 3D cell-expansion platform beyond biologics and into food, feed, and adjacent protein markets.
Why it matters for pet food
Cultivated protein is moving from pilot-scale demos to platform M&A. For pet food manufacturers, the technology offers a path to novel, traceable, and high-value ingredients—palatants, hydrolysates, and complete proteins—that are decoupled from conventional animal agriculture.
By adding Fishway, Ever After Foods gains:
- A European team and facility network for regulatory engagement
- Fish-cell cultivation expertise applicable to marine-derived pet nutrition
- Additional capacity to scale Pluri’s bioreactor platform
Deal context
The $2 million SAFE is modest compared with 2021-era alt-protein rounds, but it signals disciplined capital deployment: acquire capability, then fund scale. The transaction follows other 2025–2026 moves in the cultivated-meat and insect-protein space, including Meatly’s UK approvals, Bond Pet Foods’ fermentation work, and Innovafeed’s capacity expansions.
GlobalPetIndex view: this is the latest evidence that cultivated protein is entering an M&A phase. Pet food companies should treat novel-protein suppliers as strategic acquisition targets or partnership candidates, not just R&D curiosities.
Sources
- Pluri’s Ever After Foods Expands Cultivated-Seafood Footprint with Fishway BV — GlobeNewswire / Yahoo Finance
- Pluri’s Ever After Foods acquires Belgium-based Fishway BV — ESAA
